IDXX Quote, Financials, Valuation and Earnings

Becton Dickinson & has a net margin of 22.65% compared to IDEXX Laboratories's net margin of 5.86%. IDEXX Laboratories's return on equity of 56.57% beat Becton Dickinson &'s return on equity of 6.75%.

IDEXX Laboratories has a consensus price target of $498.01, signalling upside risk potential of 19.75%. On the other hand Becton Dickinson & has an analysts' consensus of $276.57 which suggests that it could grow by 21.57%. Given that Becton Dickinson & has higher upside potential than IDEXX Laboratories, analysts believe Becton Dickinson & is more attractive than IDEXX Laboratories.

IDEXX Laboratories has a beta of 1.391, which suggesting that the stock is 39.131% more volatile than S&P 500. In comparison Becton Dickinson & has a beta of 0.355, suggesting its less volatile than the S&P 500 by 64.526%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Becton Dickinson & offers a yield of 1.75% to investors and pays a quarterly dividend of $1.04 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Becton Dickinson & pays out 64.52% of its earnings as a dividend. Becton Dickinson &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IDEXX Laboratories quarterly revenues are $954.3M, which are smaller than Becton Dickinson & quarterly revenues of $5.2B. IDEXX Laboratories's net income of $216.1M is lower than Becton Dickinson &'s net income of $303M. Notably, IDEXX Laboratories's price-to-earnings ratio is 38.98x while Becton Dickinson &'s PE ratio is 37.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 8.88x versus 3.20x for Becton Dickinson &. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 22.65% compared to IDEXX Laboratories's net margin of -117.16%. IDEXX Laboratories's return on equity of 56.57% beat Moderna's return on equity of -29.09%.

IDEXX Laboratories has a consensus price target of $498.01, signalling upside risk potential of 19.75%. On the other hand Moderna has an analysts' consensus of $53.44 which suggests that it could grow by 74.24%. Given that Moderna has higher upside potential than IDEXX Laboratories, analysts believe Moderna is more attractive than IDEXX Laboratories.

IDEXX Laboratories has a beta of 1.391, which suggesting that the stock is 39.131% more volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

IDEXX Laboratories quarterly revenues are $954.3M, which are smaller than Moderna quarterly revenues of $956M. IDEXX Laboratories's net income of $216.1M is higher than Moderna's net income of -$1.1B. Notably, IDEXX Laboratories's price-to-earnings ratio is 38.98x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 8.88x versus 3.77x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 22.65% compared to IDEXX Laboratories's net margin of 24.22%. IDEXX Laboratories's return on equity of 56.57% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

IDEXX Laboratories has a consensus price target of $498.01, signalling upside risk potential of 19.75%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $923.05 which suggests that it could grow by 44.82%. Given that Regeneron Pharmaceuticals has higher upside potential than IDEXX Laboratories, analysts believe Regeneron Pharmaceuticals is more attractive than IDEXX Laboratories.

IDEXX Laboratories has a beta of 1.391, which suggesting that the stock is 39.131% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.270, suggesting its less volatile than the S&P 500 by 72.991%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.14% to investors and pays a quarterly dividend of $0.88 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

IDEXX Laboratories quarterly revenues are $954.3M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. IDEXX Laboratories's net income of $216.1M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, IDEXX Laboratories's price-to-earnings ratio is 38.98x while Regeneron Pharmaceuticals's PE ratio is 16.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 8.88x versus 5.16x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis has a net margin of 22.65% compared to IDEXX Laboratories's net margin of 25.08%. IDEXX Laboratories's return on equity of 56.57% beat Zoetis's return on equity of 49.71%.

IDEXX Laboratories has a consensus price target of $498.01, signalling upside risk potential of 19.75%. On the other hand Zoetis has an analysts' consensus of $199.99 which suggests that it could grow by 22.61%. Given that Zoetis has higher upside potential than IDEXX Laboratories, analysts believe Zoetis is more attractive than IDEXX Laboratories.

IDEXX Laboratories has a beta of 1.391, which suggesting that the stock is 39.131% more volatile than S&P 500. In comparison Zoetis has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.862%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.1% to investors and pays a quarterly dividend of $0.50 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Zoetis pays out 31.62% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IDEXX Laboratories quarterly revenues are $954.3M, which are smaller than Zoetis quarterly revenues of $2.3B. IDEXX Laboratories's net income of $216.1M is lower than Zoetis's net income of $581M. Notably, IDEXX Laboratories's price-to-earnings ratio is 38.98x while Zoetis's PE ratio is 29.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 8.88x versus 8.02x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.